Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: viral haemorrhagic fever therapeutics - Alnylam/USAMRIID

Drug Profile

Research programme: viral haemorrhagic fever therapeutics - Alnylam/USAMRIID

Alternative Names: VP35 siRNA - Alnylam

Latest Information Update: 22 Oct 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alnylam Pharmaceuticals; United States Army Medical Research Institute of Infectious Diseases
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Viral haemorrhagic fevers

Most Recent Events

  • 22 Oct 2013 Discontinued - Preclinical for Viral haemorrhagic fevers in USA (Parenteral)
  • 31 Dec 2011 No development reported - Preclinical for Viral haemorrhagic fevers in USA (Parenteral)
  • 07 Aug 2008 Alnylam is awarded continued funding of $US7.5 million from the US NIAID to support development of an RNAi therapeutic against viral haemorrhagic fevers (including Ebola)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top